Lopinavir/ritonavir + tenofovir + nucleoside — Competitive Intelligence Brief

Lopinavir/ritonavir + tenofovir + nucleoside (Lopinavir/ritonavir + tenofovir + nucleoside) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination therapy (protease inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors). Area: Inf

phase 3 Antiretroviral combination therapy (protease inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors) HIV protease, HIV reverse transcriptase Infectious Disease / Virology Small molecule

Target snapshot

Lopinavir/ritonavir + tenofovir + nucleoside (Lopinavir/ritonavir + tenofovir + nucleoside) — Bristol-Myers Squibb. This combination inhibits HIV protease and reverse transcriptase to block viral replication at multiple steps in the HIV life cycle.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lopinavir/ritonavir + tenofovir + nucleoside TARGET	Lopinavir/ritonavir + tenofovir + nucleoside	Bristol-Myers Squibb	phase 3	Antiretroviral combination therapy (protease inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase
Ritonavir boosted Atazanavir + 2 NRTIs	Ritonavir boosted Atazanavir + 2 NRTIs	Fundacion SEIMC-GESIDA	marketed	Protease inhibitor combination antiretroviral therapy	HIV protease, HIV reverse transcriptase
Atazanavir-Ritonavir/ Stavidine / Lamivudine	Atazanavir-Ritonavir/ Stavidine / Lamivudine	Bristol-Myers Squibb	marketed	Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase
Darunavir, Ritonavir and Etravirine	Darunavir, Ritonavir and Etravirine	Imperial College London	marketed	Antiretroviral combination (protease inhibitor + NNRTI)	HIV protease, HIV reverse transcriptase
Atazanavir / Ritonavir + Tenofovir / Emtricitabine	Atazanavir / Ritonavir + Tenofovir / Emtricitabine	Juan A. Arnaiz	marketed	Antiretroviral combination (protease inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase
Darunavir, Ritonavir and Rilpivirine	Darunavir, Ritonavir and Rilpivirine	St Stephens Aids Trust	marketed	Antiretroviral combination (protease inhibitor + NNRTI)	HIV protease, HIV reverse transcriptase
Lopinavir/ritonavir + zidovudine + lamivudine	Lopinavir/ritonavir + zidovudine + lamivudine	Amsterdam UMC, location VUmc	marketed	Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination therapy (protease inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors) class)

1. Bristol-Myers Squibb · 1 drug in this class